Panzyga not checked

Octapharma

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
3 active
7 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Newnorm is a 20% human normal immunoglobulin for SC infusion.”In the company’s words, NCT04640142 on ClinicalTrials.gov
Tested for
Primary Immune Deficiency, Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Main trialPhase 3
“Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases”In the company’s words, NCT04640142 on ClinicalTrials.gov
Other names
NewGam · Newnorm

Other drugs for Primary Immune Deficiency

All 29 drugs for Primary Immune Deficiency

Coming up3

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Nov 2026 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Phase 3Recruiting 31 Dec 2028 Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Phase 3Recruiting Dec 2029 Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Phase 4Terminated 19 Sep 2023 Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Phase 3Completed 5 Sep 2019 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Phase 3Completed 27 Aug 2024 Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Phase 3Completed 19 Sep 2025 Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Panzyga

Following is part of Solo: you see every change to Panzyga the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in